☆ 4.6 Review

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma A Review

JAMA ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Exploring a new pathway for biomarker-based approval of immunotherapies

Josep M. Llovet

Summary: The rapid progress of immunotherapy revolution in oncology lacks the development of companion diagnostic biomarkers to identify ideal target populations. In addition to the established regulatory pathways relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could significantly enhance the cost-effectiveness of cancer immunotherapy.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Philipp K. Haber et al.

Summary: This study analyzed tumor samples from patients with advanced hepatocellular carcinoma (aHCC) treated with anti-PD1 and identified interferon signaling and major histocompatibility complex-related genes as key molecular features of HCCs responding to anti-PD1. The researchers developed an 11-gene signature that can predict treatment response and survival in frontline aHCC patients.

GASTROENTEROLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Amit G. Singal et al.

HEPATOLOGY (2023)

添加到收藏夹

Meeting Abstract Oncology

Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study

Shukui Qin et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Anthony B. El-Khoueiry et al.

Summary: This retrospective analysis evaluated the efficacy of cabozantinib in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis. The results showed that cabozantinib improved overall survival and progression-free survival in these patients, with a safety profile consistent with the overall population.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma

Roger Esteban-Fabro et al.

Summary: The combination of cabozantinib and anti-PD1 has shown enhanced antitumor immunity in the treatment of advanced hepatocellular carcinoma (HCC). The combination therapy increases immune cell infiltration, reduces regulatory T cell infiltration, and alters cell proportions in the blood. It is also associated with less aggressive tumor phenotypes in HCC patients.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Grace L. Su et al.

Summary: This article presents the research and recommendations for systemic therapies for HCC, providing evidence-based guidelines for patients.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study

Antonio D'Alessio et al.

Summary: This study confirms the reproducible safety and efficacy of AtezoBev in routine clinical practice. Patients with impaired liver function (CP-B) showed comparable tolerability to those with normal liver function (CP-A), indicating the need for prospective evaluation in this specific population.

HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?

Nathan Cherny

Summary: This Perspective evaluates the FDA approvals of therapeutic agents for use in solid tumour oncology for the period 2017-2021 against the aspirations of the Cancer Moonshot. The results indicate a low level of clinical benefit for a substantial proportion of the new indications, highlighting the need for improvement in the quality of approved treatments.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu et al.

Summary: This study analyzed tumor samples from patients with hepatocellular carcinoma and found that combination therapy with atezolizumab and bevacizumab was effective in treating this type of cancer. Patients with high expression of VEGF Receptor 2, regulatory T cells, and myeloid inflammation signatures showed better outcomes with the combination therapy compared to atezolizumab alone. These findings provide insights into baseline immune and genetic features that can identify patients who will benefit from the combination therapy of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

NATURE MEDICINE (2022)

添加到收藏夹

Meeting Abstract Oncology

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R. S. Finn et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2

Richard S. Finn et al.

Summary: This study aimed to investigate the efficacy and safety of ramucirumab following non-sorafenib therapies in advanced hepatocellular carcinoma (HCC) patients. The results showed consistent and meaningful clinical activity of ramucirumab in these patients, with no new safety concerns.

ONCOLOGIST (2022)

添加到收藏夹

Review Oncology

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: In this article, Llovet and colleagues review recent advances in hepatocellular carcinoma therapy and discuss the clinical workflows for selecting and monitoring patients. The article covers the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity, and effective systemic therapies including immunotherapy. The authors propose a flowchart of sequential therapies, explore mechanisms of resistance, and address the need for predictive biomarkers.

NATURE CANCER (2022)

添加到收藏夹

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A. Vogel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Jeffrey Sum Lung Wong et al.

Summary: The combination of ipilimumab and anti-PD-1 ICIs (nivolumab or pembrolizumab) shows durable antitumor activity and encouraging survival outcomes with acceptable toxicity in patients with advanced HCC who had prior treatment with ICIs, as demonstrated in this study.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)

Philipp K. Haber et al.

Summary: A review of 49 high-quality phase III randomized controlled trials in hepatocellular carcinoma conducted between 2002 and 2020 found that 9 had positive results, suggesting that immunotherapies may be more effective in viral etiologies.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

Masatoshi Kudo et al.

Summary: Nivolumab monotherapy showed clinical activity and favorable safety in patients with Child-Pugh B status aHCC, with manageable treatment-related adverse events, suggesting its suitability for this patient population.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).

Richard S. Finn et al.

CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis

Jianchun Duan et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Bruno Sangro et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S Lee et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma A Systematic Review and Network Meta-analysis

Mohamad Bassam Sonbol et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The Use of (Network) Meta-Analysis in Clinical Oncology

Emil ter Veer et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules

Urania Dafni et al.

ESMO OPEN (2017)

添加到收藏夹

Article Oncology

ESMO-Magnitude of Clinical Benefit Scale version 1.1

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Jorge A. Marrero et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Oncology

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Review Gastroenterology & Hepatology

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

G D'Amico et al.

JOURNAL OF HEPATOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.